Steroid producing tumor

During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment. During this time the patient is vulnerable to any stressful situation. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every six hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenal cortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenal cortical suppression for 1¼ to 1½ days following a single dose) and thus are recommended for alternate day therapy.

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma.  If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.  Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids.  Edema may occur occasionally with or without congestive heart failure.  Concomitant administration of adrenal steroids or ACTH may add to the edema.  In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.   The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

The survival rate of patients with adult granulosa cell tumors is approximately 90% at 10 years but drops to approximately 50% at 30 years because of the frequency of late recurrences, which have been reported more than 30 years after surgery. 8 , 9 , 10 Despite their more malignant histologic appearance, juvenile granulosa cell tumors are associated with a better prognosis, with a survival rate of approximately 90%, and a rarity of late recurrences. 4 Inhibin 11 is available to aid in detecting the presence of recurrent granulosa cell tumor, and immunostaining for inhibin may be of great value in the pathologic differential diagnosis of granulosa cell tumors and, indeed, other sex cord-stromal tumors. 12

Steroid producing tumor

steroid producing tumor


steroid producing tumorsteroid producing tumorsteroid producing tumorsteroid producing tumorsteroid producing tumor